Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 Combined With Bevacizumab and Serplulimab in mCRC After Cytoreductive Surgery
NCT06882915Phase 1Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jun 2026
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of trifluridine + tipiracil, bevacizumab and serplulimab in colorectal cancer (CRC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Progression-free survival at 2 years. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
trifluridine + tipiracilbevacizumabserplulimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06882915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06882915.